Sutro Biopharma STRO Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $102.48M+65.2% | $62.04M-59.6% | $153.73M+127% | $67.77M+9.5% | ||
| $166.42M-34.0% | $252.04M+39.7% | $180.43M+31.5% | $137.17M+31.4% | ||
| $41.02M-15.3% | $48.45M-22.6% | $62.58M+5.1% | $59.54M+6.3% | ||
| $260.85M-13.2% | $300.5M+23.7% | $243.01M+23.5% | $196.72M+22.6% | ||
| -$158.37M+33.6% | -$238.45M— | —— | -$128.94M-30.9% | ||
| -154.5%+230pp | -384.3%— | —— | -190.3%-31.0pp | ||
| -$191.18M+15.1% | -$225.1M— | —— | -$116.7M-10.6% | ||
| -$93K-104% | $2.36M-87.0% | $18.19M— | —— | ||
| -$191.09M+16.0% | -$227.46M— | —— | -$119.2M-12.9% | ||
| -186.5%+180pp | -366.6%— | —— | -175.9%-5.3pp | ||
| -$30.67-5.4% | -$29.10— | —— | -$2.37-3.5% | ||
| -$151.04M+34.7% | -$231.24M— | —— | -$123.25M-31.6% | ||
| -147.4%+225pp | -372.7%— | —— | -181.9%-30.5pp | ||
| -$158.37M+33.6% | -$238.45M— | —— | -$128.94M-30.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Sutro Biopharma's revenue?
- Sutro Biopharma (STRO) generated $99.6M in revenue over the trailing twelve months, up 49.9% year over year.
- Is Sutro Biopharma profitable?
- Sutro Biopharma is not currently profitable: it reported a net loss of $153.6M over the trailing twelve months, a -154.2% net margin.
- What is Sutro Biopharma's earnings per share?
- Sutro Biopharma's diluted EPS over the trailing twelve months is $-24.53.
- Where does Sutro Biopharma's income statement data come from?
- Every line is extracted from Sutro Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
